Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
<p><b>Background</b></p> Mepolizumab is an anti-interleukin-5 monoclonal antibody treatment for severe eosinophilic asthma (SEA) that reduces asthma exacerbations. Residual airway inflammation on mepolizumab may lead to persistent exacerbations. Oral corticosteroids remain th...
| Päätekijät: | , , , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
Elsevier
2024
|